Yeo W et al. |
Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. |
2018 |
Hong Kong Med J |
pmid:29326401
|
Gligorov J et al. |
Emilia: use cunning to survive cancer. |
2018 |
Chin Clin Oncol |
pmid:29307196
|
Schwarz LJ et al. |
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. |
2017 |
J. Natl. Cancer Inst. |
pmid:29059433
|
La Monica S et al. |
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. |
2017 |
J. Exp. Clin. Cancer Res. |
pmid:29202823
|
Fabi A et al. |
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? |
2017 |
Future Oncol |
pmid:29182361
|
Zhang J et al. |
Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis. |
2017 |
Drug Des Devel Ther |
pmid:29180848
|
Daniels B et al. |
Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort. |
2017 |
BMJ Open |
pmid:28119394
|
Kosmin M et al. |
Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer. |
2017 |
Target Oncol |
pmid:28110417
|
Andreev J et al. |
Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs. |
2017 |
Mol. Cancer Ther. |
pmid:28108597
|
Schönfeld K et al. |
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. |
2017 |
J Hematol Oncol |
pmid:28077160
|
Moore KN et al. |
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. |
2017 |
J. Clin. Oncol. |
pmid:28029313
|
Geraud A et al. |
Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer. |
2017 |
J. Neurooncol. |
pmid:27995546
|
Mercogliano MF et al. |
TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer. |
2017 |
Clin. Cancer Res. |
pmid:27698002
|
Baldassarre T et al. |
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers. |
2017 |
Breast Cancer Res. |
pmid:28974266
|
Wang H et al. |
Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. |
2017 |
Cancer Sci. |
pmid:28388007
|
Lambert JM and Morris CQ |
Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. |
2017 |
Adv Ther |
pmid:28361465
|
Socinski MA et al. |
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. |
2017 |
Clin Lung Cancer |
pmid:28341109
|
Carvajal-Hausdorf DE et al. |
Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. |
2017 |
Gynecol. Oncol. |
pmid:28196634
|
Perez EA et al. |
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. |
2017 |
J. Clin. Oncol. |
pmid:28056202
|
Parikh A et al. |
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. |
2017 |
J Natl Compr Canc Netw |
pmid:28040715
|